Table 3. Base case results for the 40–49 age group when lifetime horizon is used.
| Adjuvant Treatment |
Total Cost (2016 USD) |
QALYs | Incremental costs a | Incremental QALYs a | ICER |
| (Base case) | |||||
| NT | $ 108,821 | 9.57 | $ -69,829 | -6.6 | — |
| TH | $ 178,650 | 16.17 | — | — | $ 10,584 / QALY b |
| ACTH | $ 221,974 | 15.46 | $ 43,324 | -0.71 | N/A a |
| TCH | $ 198,473 | 15.02 | $ 19,823 | -1.15 | N/A a |
| (Without adjustment for quality of life) | Total Cost | LYs | Incremental costs | Incremental LYs | ICER |
| NT | $ 108,821 | 18.87 | $ -69,829 | -14.9 | — |
| TH | $ 178,650 | 33.77 | — | — | $ 4,688 / LY b |
| ACTH | $ 221,974 | 32.25 | $ 43,324 | -1.52 | N/A a |
| TCH | $ 198,473 | 31.23 | $ 19,823 | -2.54 | N/A a |
a Not applicable.
b Relative to NT.
Abbreviations: ACTH, doxorubicin, cyclophosphamide, paclitaxel and trastuzumab regimen; ICER, incremental cost-effectiveness ratio; NT, no adjuvant trastuzumab regimen; QALY, quality-adjusted life year; TCH, docetaxel, carboplatin and trastuzumab regimen; TH, adjuvant paclitaxel and trastuzumab regimen.